Panion Animal Health AB develops a unique gene therapy treatment for dogs with idiopathic epilepsy. A safety study in dogs is currently running at the University of Copenhagen under the lead of Associate Professor David Woldbye, Department of Neuroscience, KU. Preliminary results from the study were expected in Q2, but due to circumstances outside Panion’s influence, Panion has just been informed that this timing has been slightly delayed into Q3.

“The access to gene therapy facilities at Copenhagen University is limited and the study was confronted with overbooking and issues with availability of staff and equipment. We wish to inform the market about this slight delay to maintain the trust in our information flow and to avoid speculations. It is important to note that nothing negative has been seen in the study so far, and that we are fully confident with the study conduct” says CEO in Panion, Anja Holm.